Business
Edgewise to Present Data on EDG-7500 at the American Heart Association’s Scientific Sessions 2023
BOULDER, Colo.--(BUSINESS WIRE)-- Edgewise Therapeutics, Inc., (Nasdaq: EWTX), a leading muscle disease biopharmaceutical company, today announced that the
About this update from Edgewise Therapeutics, Inc.
[{"type":"text","content":" BOULDER, Colo.--(BUSINESS WIRE)--\nEdgewise Therapeutics, Inc., (Nasdaq: EWTX), a leading muscle disease biopharmaceutical company, today announced that the Company will present the results of nonclinical studies of EDG-7500 at the American Heart Association’s (AHA) Scientific Sessions 2023 being held in Philadelphia from November 11 - 13. EDG-7500 is a first-in-class oral, selective, cardiac sarcomere modulator, specifically designed to slow early contraction velocity and address impaired cardiac relaxation associated with hypertrophic cardiomyopathy (HCM) and other diseases of diastolic dysfunction.\n\n\nDetails of the Rapid Fire Oral Presentation:\n\n\nTitle: EDG-7500, a Novel Cardiac Sarcomere Regulator That Preserves Intrinsic Myosin-Motor Function, Improves Cardiac Function and Reserve in a Minipig Model of Hypertrophic Cardiomyopathy\nSession: The Pharmacologic Management of Heart Failure: Beyond Guidelines and Paradigms\nDate and Time: Monday, November 13, 2023, 2:20 – 2:25 pm ET\n\n\nDetails of the Scientific Poster Presentation:\n\n\nTitle: Cardiac Effects of EDG-7500, a Novel Cardiac Sarcomere Regulator: In Vitro and In Vivo Evidence for Slowing Isovolumic Contraction and Improved Ventricular Compliance (Board #2163)\nSession: Bench to Bedside: Novel Therapeutic Approaches in Heart Failure\nDate and Time: Saturday, November 11, 2023, 11:30 am – 12:45 pm ET\n\n\nThe AHA Scientific Sessions’ program is available here. The Edgewise presentation and poster will be available on the Edgewise website when they are presented.\n\n\nAbout EDG-7500 for Hypertrophic Cardiomyopathy\n\n\nEDG-7500 is a first-in-class oral, selective, cardiac sarcomere modulator produced by the Company’s robust discovery platform. The compound is specifically designed to slow early contraction velocity and address impaired cardiac relaxation associated with HCM and other diseases of diastolic dysfunction. The Company is enrolling a Phase 1 randomized, double-blind, placebo-controlled, single and multiple ascending dose study of EDG-7500 evaluating safety, tolerability, pharmacokinetics and pharmacodynamics in healthy adults. To learn more about this study (NCT06011317), go to clinicaltrials.gov. The Company is also planning to begin a Phase 1b study of EDG-7500 in individuals with obstructive HCM in the first half of 2024.\n\n\nAbout Hypertrophic Ca...